Table 1.
Clinical characteristics of the patients.
| Parameter | Overall | CellSearch® System | EPISPOT | CellCollector® | Combined | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTC Negative | CTC Positive | p-Value | CTC Negative | CTC Positive | p-Value | CTC Negative | CTC Positive | p-Value | CTC Negative | CTC Positive | p-Value | ||
| Patients, n (%) | 131 | 94 (82) | 20 (18) | 67 (54) | 57 (46) | 60 (48) | 66 (52) | 16 (12) | 115 (88) | ||||
| Age, Median (IQR), Min–Max | 68.5, (64.25–72), 51–89 | 68 (64–72) 51–80 | 70.5 (66.75–72.75) 60–89 | 0.15 | 69 (66–72) 53–89 | 66 (63–72) 51–79 | 0.053 | 69 (64–72) 51–89 | 67 (64.25–72) 53–78 | 0.50 | 69, (67.5–72.25), 59–80 | 68, (64–72), 51–89 | 0.22 |
| BMI, Median (IQR), Min–Max | 27.61, (25.6–29.8), 20.45–46.17 | 27.4, (25.5–29.7), 20.8–46.17 | 28.01, (26.8–29.4), 23.2–41.9 | 0.37 | 27.13, (25.5–29.5), 20.8–41.91 | 27.7, (26.03–30.67), 20.45–37.18 | 0.33 | 27.46, (25.24–29.11), 20.45–37.18 | 27.68, (26.17–31.7), 21.51–46.17 | 0.19 | 25.59, (23.5–26.9), 20.8–29.4 | 27.68, (26.12–30.66), 20.45–46.17 | 0.0036 |
| PSA, Median (IQR), Min–Max | 27.85, (15–35–40.75), 0.5–191 | 28.2 (20–42) 3.89–191 | 25.6 (7–09–40.25) 0.5–172 | 0.26 | 26.795 (10.365–41.15) 0.5–172 | 28.2 (17.6–40) 5–191 | 0.23 | 25 (10.5–41.1) 2.5–191 | 28.5 (22.5–37) 0.5–136.9 | 0.23 | 24.83, (11.78–38.95), 3.9–66 | 28.05, (15.625–40.75), 0.5–191 | 0.49 |
| Biopsy Gleason score; n (%) | |||||||||||||
| 3+3 | 30 (23) | 22 (23.9) | 4 (20) | 0.77 | 13 (19.7) | 15 (26.8) | 0.069 | 13 (22) | 17 (25.8) | 0.14 | 3 (18.8) | 27 (23.9) | 0.35 |
| 3+4 | 40 (31) | 30 (32.6) | 4 (20) | 18 (27.3) | 20 (35.7) | 19 (32.2) | 21 (31.8) | 4 (25) | 36 (31.8) | ||||
| 4+3 | 24 (19) | 19 (20.7) | 2 (10) | 10 (15.2) | 12 (21.4) | 10 (16.9) | 12 (18.2) | 4 (25) | 20 (17.7) | ||||
| ≥4+4 | 35 (28) | 21 (22.8) | 10 (50) | 25 (37.8) | 9 (16.1) | 17 (28.9) | 16 (24.2) | 5 (31.2) | 30 (26.6) | ||||
| Clinical T stage; n (%) | |||||||||||||
| T1a | 1 (0.8) | 0 (0) | 0 (0) | 0.64 | 0 (0) | 1 (1.8) | 0.078 | 0 (0) | 1 (1.6) | 0.24 | 0 (0) | 1 (0.9) | 0.95 |
| T1c | 76 (60.3) | 56 (62.2) | 9 (47.4) | 36 (55.4) | 35 (63.6) | 31 (53.4) | 45 (70.3) | 10 (62.5) | 66 (60) | ||||
| T2a | 10 (7.9) | 6 (6.7) | 3 (15.8) | 4 (6.2) | 6 (10.9) | 7 (12.1) | 3 (4.7) | 1 (6.2) | 9 (8.2) | ||||
| T2b | 3 (2.4) | 3 (3.3) | 0 (0) | 2 (3.1) | 0 (0) | 1 (1.7) | 2 (3.1) | 0 (0) | 3 (2.7) | ||||
| T2c | 23 (18.3) | 16 (17.8) | 4 (21.1) | 13 (20) | 10 (18.2) | 12 (20.7) | 9 (14.1) | 3 (18.8) | 20 (18.2) | ||||
| T3a | 12 (9.5) | 8 (8.9) | 3 (15.8) | 10 (15.4) | 2 (3.6) | 6 (10.3) | 4 (6.2) | 2 (12.5) | 10 (9.1) | ||||
| T3b | 1 (0.8) | 1 (1.1) | 0 (0) | 0 (0) | 1 (1.8) | 1 (1.7) | 0 (0) | 0 (0) | 1 (0.9) | ||||
BMI, body mass index; PSA, prostate specific antigen.